Bergen, 30th May 2007: NorDiag has signed a non exclusive distribution agreement with Roche Diagnostics Scandinavia AB where Roche will lease instruments and purchase kits from NorDiag for resale to their customers in the field of sexually transmitted diseases.

The first phase of the contract concludes a lease of six instruments that are already in routine use by customers in the Swedish market. The value of the contract is approximately NOK 6,5 million.

“This is part of our ambition to be a leading supplier of automated systems for isolating DNA from difficult clinical samples. We are honoured to be the supplier of choice to the largest diagnostic company in the world. We have previously landed a similar agreement with Roche Finland. Once again we have proven to be a front runner in this field, which we believe we can capitalize on when expanding to other European countries, USA and Far East, says CEO Mårten Wigstøl.

NorDiag offers automated solutions (instruments, software and kits) for preparation of samples for sexually transmitted diseases, tuberculosis and MRSA, while similar systems for colon cancer and respiratory pathogens are in pipeline.

Contact person: CEO Mårten Wigstøl, mob. +47 911 657 75

About NorDiag ASA
NorDiag is a biotechnology company with focus on gene based diagnostics in the fields of cancer and infectious diseases. The Company’s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline. NorDiag is listed on Oslo Stock Exchange with ticker NORD. Additional information is available on the Internet at www.nordiag.no.

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our website at www.roche.com.